Kurt Lock

发表

Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial.

M. Schechter, A. Anis, D. Guh, 2016, JAMA psychiatry.

Hydromorphone ComparedWith Diacetylmorphine for Long-termOpioid Dependence A Randomized Clinical Trial

M. Schechter, A. Anis, D. Guh, 2016 .

The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency

M. Schechter, D. Guh, Kirsten Marchand, 2015, Substance Abuse Treatment, Prevention, and Policy.

Men’s and women’s response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder

M. Schechter, A. Anis, D. Guh, 2017, Substance Abuse Treatment, Prevention, and Policy.

Guideline development in harm reduction: Considerations around the meaningful involvement of people who access services

Jenny McDougall, Alissa M. Greer, Kurt Lock, 2022, Drug and alcohol dependence reports.

Evaluation of risk mitigation measures for people with substance use disorders to address the dual public health crises of COVID-19 and overdose in British Columbia: a mixed-method study protocol

A. Slaunwhite, K. Card, B. Barker, 2020, BMJ Open.

Identifying behaviours for survival and wellness among people who use methamphetamine with opioids in British Columbia: a qualitative study

H. Spence, Jenny McDougall, Heather Palis, 2022, Harm Reduction Journal.

Predictors of non-use of illicit heroin in opioid injection maintenance treatment of long-term heroin dependence.

M. Schechter, A. Anis, D. Guh, 2015, Addictive behaviors.

Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with injectable opioid agonist treatment patients

D. Marsh, Heather Palis, Kirsten Marchand, 2021 .

Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods.

M. Schechter, A. Anis, D. Guh, 2019, Journal of substance abuse treatment.

Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study

N. Bansback, M. Schechter, Scott Harrison, 2022, Patient preference and adherence.

PPA_A_391532 3405..3413

N. Bansback, M. Schechter, Scott Harrison, 2022 .

History of Treatment Access and Drug Use among Participants in a Trial Testing Injectable Opioids under Supervision for Long-Term Heroin Injectors

M. Schechter, A. Anis, D. Guh, 2015 .

Correlates of concurrent use of stimulants and opioids among people who access harm reduction services in British Columbia, Canada: Findings from the 2019 Harm Reduction Client Survey.

K. Papamihali, J. Buxton, Kurt Lock, 2022, The International journal on drug policy.

Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long‐term opioid dependence

M. Schechter, A. Anis, D. Guh, 2018, Drug and alcohol review.

Concurrent use of opioids and stimulants and risk of fatal overdose: A cohort study

A. Slaunwhite, Heather Palis, S. Dobrer, 2022, BMC Public Health.

Motivations for concurrent use of uppers and downers among people who access harm reduction services in British Columbia, Canada: findings from the 2019 Harm Reduction Client Survey

K. Papamihali, J. Buxton, Kurt Lock, 2022, BMJ Open.

Predictors of treatment allocation guesses in a randomized controlled trial testing double-blind injectable hydromorphone and diacetylmorphine for severe opioid use disorder

M. Schechter, A. Anis, D. Guh, 2017 .

The association between nicotine dependence and physical health among people receiving injectable diacetylmorphine or hydromorphone for the treatment of chronic opioid use disorder

M. Schechter, A. Anis, D. Guh, 2018, Addictive behaviors reports.

“As long as that place stays open, I’ll stay alive”: Accessing injectable opioid agonist treatment during dual public health crises

Kaitlyn Jaffe, Scott Harrison, E. Oviedo-Joekes, 2023, Harm Reduction Journal.

Smoking identified as preferred mode of opioid safe supply use; investigating correlates of smoking preference through a 2021 cross-sectional study in British Columbia

Kurt Lock, J. Buxton, B. Graham, 2023, Substance Abuse Treatment, Prevention, and Policy.

A chance to stop and breathe: participants’ experiences in the North American Opiate Medication Initiative clinical trial

M. Schechter, A. Anis, J. Chettiar, 2014, Addiction Science & Clinical Practice.

A multi-methods and longitudinal study of patients' perceptions in injectable opioid agonist treatment: Implications for advancing patient-centered methodologies in substance use research.

M. Schechter, D. Guh, D. Marsh, 2021, Journal of substance abuse treatment.

Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with patients receiving injectable opioid agonist treatment

M. Schechter, D. Marsh, Heather Palis, 2021, Substance Abuse Treatment, Prevention, and Policy.

Awareness, predictors and outcomes of drug alerts among people who access harm reduction services in British Columbia, Canada: findings from a 2021 cross-sectional survey

Jenny McDougall, Kurt Lock, J. Buxton, 2023, BMJ Open.

Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatment

M. Schechter, A. Anis, D. Guh, 2014, Substance Abuse Treatment, Prevention, and Policy.

“It’s just a perfect storm”: Exploring the consequences of the COVID-19 pandemic on overdose risk in British Columbia from the perspectives of people who use substances

Jenny McDougall, Kurt Lock, J. Buxton, 2023, BMC Public Health.